Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

Abstract

Allogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only curative treatment modality for myelodysplastic syndromes (MDS). The treatment paradigm for MDS has changed in recent years with the introduction of hypomethylating agents (HMAs). The present retrospective multicenter study was designed to assess the effects of pre-transplant HMA on transplant outcome and determine which patients would benefit most from this therapy. A total of 109 patients who received alloSCT at one of five institutions between 2007 and 2010 were enrolled in this study regardless of pre-transplant HMA therapy. 81 of the 109 patients enrolled were treated with HMA prior to alloSCT. 28 patients received alloSCT without HMA bridging. The distributions of WHO classification groups and IPSS scores were similar between the two groups (P = 0.752 and P = 0.265, respectively). Pre-transplant HMA did not affect OS (P = 0.244), and there were no differences in response to HMA therapy within the HMA-treated group. The cumulative incidence of NRM was not significantly different between the two groups (P = 0.500). However, for patients with a high blast count (>5 % of bone marrow at the time of diagnosis), pre-transplant HMA therapy had a NRM benefit (83.3 vs. 48.6 %, P = 0.014).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Cazzole M, Malcovati L. Myelodysplastic syndromes––coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–8.

    Article  Google Scholar 

  2. 2.

    Schiffer CA. Clinical issues in the management of patients with myelodysplasia. Hematol Am Soc Hematol Edu Progr. 2006;1:205–10.

    Google Scholar 

  3. 3.

    Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–40.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–803.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76(3):218–27.

    PubMed Central  PubMed  Article  Google Scholar 

  6. 6.

    Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100(6):1997–2004.

    CAS  PubMed  Google Scholar 

  7. 7.

    Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4):1201–7.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395–400.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324–41.

    CAS  PubMed  Google Scholar 

  10. 10.

    Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylating: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–96.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999;9(5):359–67.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Cooper DN. Eukaryotic DNA methylation. Hum Genet. 1983;64(4):315–33.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85–93.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Ando T, Nishimura M, Oka Y. Decitabine (5-aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia. 2000;14(11):1915–20.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Ley TJ, Anagnou NP, Noguchi CT, Schechter AN, DeSimone J, Heller P, et al. DNA methylation and globin gene expression in patients treated with 5-azacytidine. Prog Clin Biol Res. 1983;134:457–74.

    CAS  PubMed  Google Scholar 

  16. 16.

    Gattei V, Aldinucci D, Petti MC, Da Ponte A, Zagonel V, Pinto A. In vitro and in vivo effects of 5-aza-2′-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. Leukemia. 1993;7(Suppl 1):42–8.

    PubMed  Google Scholar 

  17. 17.

    Corey C. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematol Am Soc Hematol Edu Progr. 2010;2010:325–9.

    Article  Google Scholar 

  18. 18.

    De Silva Padua L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transpl. 2009;43(11):839–43.

    Article  Google Scholar 

  19. 19.

    Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2010;45(2):255–60.

    CAS  Article  Google Scholar 

  20. 20.

    Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national marrow donor program. Blood. 2002;99(6):1943–51.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transpl. 2007;13(4):454–62.

    CAS  Article  Google Scholar 

  24. 24.

    Yakoub-Agha I, de La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients: report of the French Society of bone marrow transplantation. J Clin Oncol. 2000;18(5):963–71.

    CAS  PubMed  Google Scholar 

  25. 25.

    Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82(2):677–81.

    CAS  PubMed  Google Scholar 

  26. 26.

    Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. Blood. 1996;88(10):358–65.

    CAS  PubMed  Google Scholar 

  27. 27.

    Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1998;21(3):255–61.

    CAS  Article  Google Scholar 

  28. 28.

    Parmar S, de Lima M. Hematopoietic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transpl. 2010;16(1 Suppl):S37–44.

    Article  Google Scholar 

  29. 29.

    Kantarjian HM, O’Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109(6):1133–7.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  30. 30.

    Yahng Seoung-Ah, Yoon Jae-Ho, Shin Seung-Hwan, Lee Sung-Eun, Cho Byung-Sik, Lee Dong-Gun, et al. Response to pretransplant hypomethylating agents influences the outcomes of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes. Eur J Haematol. 2013;90(2):111–20.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Consortia

Corresponding authors

Correspondence to Je-Hwan Lee or June-Won Cheong.

Additional information

J.-W. Cheong and Je-Hwan Lee made equal contribution to this work as corresponding author.

About this article

Cite this article

Kim, Y., Kim, IH., Kim, H.J. et al. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. Int J Hematol 99, 635–643 (2014). https://doi.org/10.1007/s12185-014-1549-3

Download citation

Keywords

  • Myelodysplastic syndrome
  • Hypomethylating agent
  • AlloSCT